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OBJECTIVES: This study assesses the cost-effectiveness of universal vaccination
with RV5 in a hypothetical cohort of 1,091,156 children in Japan during their first 5
years of life. METHODS: A Markov model was developed to evaluate the cost per
quality-adjusted-life-year (QALY) from the healthcare and societal perspectives.
The base case scenario assumes 94% of the vaccinated cohort received 3 doses of
RV5 orally at 2, 4, and 6 months of age with the remaining children receiving only
1 or 2 doses. In the absence of a vaccination strategy, there is annually 1 death,
78,000 hospitalizations, and 739,874 outpatient visits. The efficacy of RV5 was
based on the results of the Rotavirus Efficacy and Safety Trial (REST). The three dose
efficacy in REST was similar to the one obtained from clinical trials conducted in
Japan. RESULTS: Universal vaccination could reduce hospitalizations by 89% and
all symptomatic episodes of rotavirus gastroenteritis by 59%. For the base case
scenario, at a cost of JPY 5316 per dose and administration fee of JPY ,100 per dose,
the cost per case avoided was JPY 22,704 and the cost per QALY saved was JPY
2,230,978 from the healthcare payer perspective. From the societal perspective, the
cost per case avoided was JPY 8,934 and the cost per QALY saved was JPY 877,855.
CONCLUSIONS: Using three times the GDP per capita as a threshold, universal
vaccination with RV5 is likely to be cost-effective and to result in substantial re-
ductions in rotavirus-related healthcare use in Japan.
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UGANDA
Kuznik A, Sempa J, Ssennono M, Hermans S, Castelnuovo B, Lamorde M, Semeere A,
Auerbach B, Sowinski S, Ssewankambo F, Manabe YC
Infectious Diseases Institute, Kampala, Uganda
OBJECTIVES:According to national guidelines, HIV-positive patients in Uganda are
to be initiated on combination antiretroviral therapy (cART) at a CD4 T-cell (CD4)
count below 250 cells/l. However, cART initiation at higher CD4 counts increases
survival, albeit at higher lifetime treatment cost. This analysis evaluates the cost-
effectiveness of initiating cART at CD4 counts between 250 – 349 cells/l vs. current
guidelines. METHODS: The average CD4 decline in untreated patients with CD4
counts below 550 cells/l occurs at a rate of 96.6 cells/l annually. Life expectancy
of cART-treated patients, conditional on baseline CD4 count, is modeled based on
published literature. First line cART costs US$192 annually, with an additional
US$113 per year for patient monitoring. Delay of cART until the CD4 count falls
below 250 cells/l incurs the cost of the bi-annual CD4 test and cost of routine
maintenance care at US$85 annually. The analysis compares lifetime treatment
costs and disability adjusted life-expectancy between early vs. delayed cART for
ten baseline CD4 count ranges from 250-259 to 340-349 cells/l. All costs and ben-
efits are discounted at 3% annually. RESULTS: Treatment delay varies from 0.5 year
(CD4: 250-299) – 1 year (CD4: 300-349). Early cART initiation increases life expec-
tancy between 1.48 and 3.01 years and averts 1.31 – 2.67 disability adjusted life
years (DALY’s) per patient. Lifetime treatment costs are US$4255 – US$5210 for
early initiation and US$3755 – US$4307 for delayed initiation. The cost/DALY
averted of the early versus delayed start ranges from US$354 – US$362.
CONCLUSIONS: In HIV-positive patients presenting with CD4 counts between 250-
350 cells/l, immediate initiation of cART is a highly cost-effective strategy using
the recommended 1 time per capita GDP threshold of $460 reported for Uganda.
Expanding the number of treatment slots to include patients with higher CD4
counts would constitute an efficient use of scarce health care dollars.
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OBJECTIVES: Chronic infection with the hepatitis C virus (HCV), if not cleared, can
cause severe liver damage and eventual death. Despite treatment with current
standard of care (pegylated interferon-alfa and ribavirin (PR)), sustained virologic
response (SVR) is achieved in less than half of genotype 1 HCV patients. This anal-
ysis evaluated the cost-effectiveness of boceprevir in combination with PR in treat-
ment-naïve and previously treated genotype 1 HCV patients, based on results of the
phase III clinical trials, and from the perspective of NHS Scotland. METHODS: A
Markov model was created to simulate the three treatment strategies studied in
the boceprevir phase III trials: boceprevir response guided therapy (RGT), where a
shortened treatment duration was possible for early responders; a full duration
boceprevir arm (4 weeks PR plus 44 weeks triple therapy); and a 48 week PR stan-
dard of care arm. Each treatment regimen including boceprevir was compared to
the PR standard of care arm. The incremental cost-effectiveness ratio (ICER) was
measured in terms of cost per quality adjusted life year. The efficacy values applied
were taken from the boceprevir clinical trials. In treatment naïve patients, 63% and
66% patients achieved SVR in the boceprevir RGT and full duration arms respec-
tively, compared to 38% in the control arm. In previously treated patients, 59% and
67% patients achieved SVR in the boceprevir RGT and full duration arms respec-
tively, compared to 21% who received PR alone. RESULTS: The ICER over current
standard of care lies between £6,462 and £13,299 for treatment naïve patients and
between £5,248 and £6,684 for treatment experienced patients, depending on treat-
ment duration. CONCLUSIONS: The addition of boceprevir to current standard of
care for HCV genotype 1 patients is clinically efficacious and cost-effective, and
comfortably below a threshold of £20,000 per QALY, irrespective of whether pa-
tients have been previously treated.
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OBJECTIVES:Ventilator-associated pneumonia (VAP) is the most common nosoco-
mial infection in the intensive care unit (ICU). It’s associated with significant mor-
bidity, increasing the ICU and hospital length of stay (LOS), and raising overall
costs. Panama=s statistics are similar to those reported in developed countries.
Literature suggests that costs could be reduced using the most efficient empiric
therapy. The aim of this study was to assess the cost-effectiveness (CE) of linezolid
against generic vancomycin as an empiric therapy for VAP patients, from the
health care payer’s perspective. METHODS: A decision-tree model was used to
compare costs and effectiveness of linezolid (600mg/12 hours) and vancomycin (1g/
12 hours) (comparator) for a cohort of patients with VAP. Effectiveness measures
were: clinical and microbiological success rates, mortality rates, ICU LOS and over-
all costs. Effectiveness and epidemiologic data were collected from published lit-
erature. Local costs (2011 US$) were obtained from Panama=s Social Security official
databases. The model used a 12-week time horizon and only direct medical costs
were considered (hospital LOS, medication costs, hematologic, gastrointestinal
and skin adverse events and lab exams). Monte Carlo probabilistic sensitivity anal-
ysis (PSA) was constructed. RESULTS: Results showed linezolid as more effective
and less expensive option for VAP. Clinical success rate was higher with linezolid
(64%) against vancomicyn, (59.5%). Mortality was lower with linezolid (10.13% vs.
15.74%). Average ICU LOSs was 17.4 days with linezolid and 21.26 days with van-
comycin. Overall medical costs per patient were $19,507 with linezolid and $20,411
with vancomycin. CE analyses showed linezolid is the dominant strategy. Accept-
ability curves showed that linezolid would be cost-effective within 3 GDP per
capita threshold. PSA outcomes support the robustness of these findings.
CONCLUSIONS: This is the first CE study for VAP developed in Panamá. Linezolid
resulted as the cost-saving option for treating VAP patients in the Panamanian
clinical environment.
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OBJECTIVES: Approximately 40,000 new TB cases are treated annually in Uganda,
and 4,000 are reported to require re-treatment (category II treatment). Current
tuberculosis (TB) treatment in Uganda is standard 4 drug therapy in intensive
phase (2 months), followed by isoniazid and ethambutol for 6 months (6HE). How-
ever, the World Heath Organization recommends isoniazid and rifampicin for 4
months (4HR) in the continuation phase, which is associated with better efficacy.
We sought to investigate the cost-effectiveness of 4HR vs. 6HE. METHODS: Ran-
domized clinical trial evidence indicates a significant decrease in the rate of treat-
ment failure and relapse associated with 6HE versus 4HR from 10.0% to 5.0%. The
median international daily drug price is HR: US$0.115 and HE: US$0.069. When the
initial regimen is not successful, re-treatment is associated with a mortality rate of
up to 23% and involves an additional 8 month drug-regimen at a cost of US$39.25.
A decision tree was used to calculate the expected total cost of TB treatment in the
4HR versus 6HE arm. RESULTS: The cost of TB treatment in the continuation phase
is 4HR: US$13.82 and 6HE: US$12.46. However, once the cost of re-treatment is
factored in, the average weighted treatment cost is 4HR: US$15.79 and 6HE:
US$16.38. Replacing 6HE with 4HR nationally could decrease the annual cost of TB
treatment by an estimated US$23,500 and prevent about 2,000 TB treatment fail-
ures and relapses per year. CONCLUSIONS: Combination therapy with 4HR in the
continuation phase dominates 6HE, as it is associated with improved effectiveness
and a lower average cost per patient. Since treatment failure or relapse is associ-
ated with worsened clinical outcomes in resource constrained settings, consider-
able gains to population health could be achieved at lower cost if 4HR became the
new standard of care in the continuation phase of TB treatment in Uganda.
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OBJECTIVES: To assess cost-effectiveness of pegylated interferon alpha-2a
(PegIFN2a) vs. pegylated interferon alpha-2b (PegIFN2b) in the treatment of
chronic hepatitis C (HCV) patients from Polish public payer perspective.METHODS:
Systematic review assessed clinical efficacy and safety of the two treatment op-
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